Stock Analysis·← Pickers

CINGW

Cingulate Inc.

Cingulate Inc. (CINGW) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 46.8, with 0/3 trend checks passing.

Price
$0.02
2026-07-16
Trend score
0/3
Downtrend
RSI (14)
46.8
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

CINGW with MA50 and MA200

0.170.140.100.060.0207/0810/0901/1604/1607/15
CINGW2025-07-082026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$0.03-24.90% vs price
MA200
$0.05-55.81% vs price
RSI (14)
46.8Neutral zone
MACD Signal
MixedMACD near signal line
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for CINGW

Cingulate Inc. (CINGW) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $0.02, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 24.9% and below the 200-day moving average by 55.8%.

Momentum and stretch context

CINGW currently has an RSI reading of 46.8, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.

What traders may watch next

For traders reviewing CINGW next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.

Company profile

About Cingulate Inc.

Cingulate Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to pioneering therapies for central nervous system and neurobiological conditions. Its leading investigational medicines are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed to manage attention deficit/hyperactivity disorders (ADHD). Furthermore, the company is progressing CTx-2103 for the treatment of anxiety disorders. Established in 2012, Cingulate Inc. maintains its main office in Kansas City, Kansas, and also operates a facility in Morristown, New Jersey.

Sector
Healthcare
Industry
Biotechnology
CEO
Shane J. Schaffer
Employees
14
Market cap
$135.7K
Beta
-0.92
52-week range
$0.02 – $0.04
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
8 Dec 2021
ISIN
US17248W1137
CUSIP
17248W113
Company profile data from Financial Modeling Prep. CINGW listed on NASDAQ.
Share dilution

CINGW shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Mar 2020Mar 2026
Shares outstanding (latest)
5.4M
Since Mar 2020
+284.2%
Trend
More shares outstanding
Historical shares-outstanding data from Financial Modeling Prep. CINGW25 data points from Mar 2020 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about CINGW

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.